See more : Yotai Refractories Co., Ltd. (5357.T) Income Statement Analysis – Financial Results
Complete financial analysis of Nichi-Iko Pharmaceutical Co., Ltd. (4541.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nichi-Iko Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Enjoy Technology, Inc. (ENJY) Income Statement Analysis – Financial Results
- Watts Water Technologies, Inc. (WTS) Income Statement Analysis – Financial Results
- South Asian Enterprises Limited (SAENTER.BO) Income Statement Analysis – Financial Results
- CTS International Logistics Corporation Limited (603128.SS) Income Statement Analysis – Financial Results
- Foodfest International 2000 Inc. (FDFT) Income Statement Analysis – Financial Results
Nichi-Iko Pharmaceutical Co., Ltd. (4541.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.nichiiko.co.jp
About Nichi-Iko Pharmaceutical Co., Ltd.
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group. It primarily focuses on the production of generic drugs. The company offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems, and others. In addition, the company engages in the packaging design business. Further, it exports its products. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16,907.73B | 179.06B | 188.22B | 190.08B | 15,888.62B | 164.72B | 163.38B | 143.53B | 127.04B | 103.61B | 93.91B | 77.73B | 64.34B | 54.82B | 42.85B | 32.32B | 29.24B |
| Cost of Revenue | 13,576.13B | 175.09B | 166.97B | 152.76B | 12,524.36B | 123.91B | 106.64B | 90.00B | 79.94B | 63.95B | 57.26B | 46.42B | 36.95B | 30.05B | 22.77B | 16.73B | 15.47B |
| Gross Profit | 3,331.59B | 3.97B | 21.25B | 37.32B | 3,364.26B | 40.80B | 56.74B | 53.54B | 47.10B | 39.67B | 36.65B | 31.30B | 27.39B | 24.77B | 20.08B | 15.59B | 13.77B |
| Gross Profit Ratio | 19.70% | 2.21% | 11.29% | 19.63% | 21.17% | 24.77% | 34.73% | 37.30% | 37.08% | 38.28% | 39.02% | 40.27% | 42.57% | 45.18% | 46.87% | 48.25% | 47.09% |
| Research & Development | 880.92B | 4.25B | 4.34B | 4.26B | 806.91B | 4.47B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 27.88B | 27.03B | 25.61B | 22.50B | 23.14B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 1,740.39B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1,669.91B | 27.88B | 27.03B | 25.61B | 1,762.89B | 23.14B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 81.89B | -10.23B | 4.57B | -1.07B | 2.90B | 48.19B | 40.62B | 37.48B | 32.28B | 28.42B | 23.81B | 20.30B | 18.53B | 14.91B | 11.42B | 10.08B |
| Operating Expenses | 2,495.14B | 114.02B | 21.14B | 34.45B | 2,425.36B | 30.50B | 48.19B | 40.62B | 37.48B | 32.28B | 28.42B | 23.81B | 20.30B | 18.53B | 14.91B | 11.42B | 10.08B |
| Cost & Expenses | 11,081.00B | 289.11B | 188.11B | 187.20B | 10,099.00B | 154.41B | 154.82B | 130.62B | 117.42B | 96.23B | 85.68B | 70.24B | 57.25B | 48.58B | 37.67B | 28.15B | 25.56B |
| Interest Income | 43.11B | 3.13B | 1.33B | 111.00M | 40.48B | 76.00M | 94.00M | 102.00M | 33.00M | 20.00M | 18.26M | 13.77M | 5.42M | 3.40M | 3.01M | 3.69M | 1.75M |
| Interest Expense | 0.00 | 1.13B | 801.00M | 1.81B | 890.00M | 1.26B | 294.00M | 127.00M | 109.00M | 149.00M | 155.40M | 188.04M | 231.77M | 268.66M | 194.25M | 120.60M | 187.26M |
| Depreciation & Amortization | 1,418.16B | 15.99B | 13.22B | 11.87B | 9.40B | 8.66B | 7.40B | 5.36B | 4.99B | 6.02B | 4.77B | 4.34B | 2.92B | 1.75B | 1.06B | 797.63M | 589.32M |
| EBITDA | 2,125.82B | -94.06B | 15.09B | 21.08B | 1,448.07B | 18.99B | 14.63B | 20.84B | 14.59B | 13.23B | 13.10B | 11.11B | 9.03B | 7.48B | 6.26B | 4.88B | 4.20B |
| EBITDA Ratio | 12.57% | -52.53% | 8.02% | 11.09% | 9.11% | 11.53% | 8.95% | 14.52% | 11.48% | 12.76% | 13.95% | 14.29% | 14.03% | 13.65% | 14.61% | 15.09% | 14.37% |
| Operating Income | 780.77B | -110.05B | 1.87B | 9.21B | 794.46B | 10.30B | 8.55B | 12.91B | 9.62B | 7.39B | 8.23B | 7.49B | 7.10B | 6.25B | 5.18B | 4.17B | 3.69B |
| Operating Income Ratio | 4.62% | -61.46% | 0.99% | 4.84% | 5.00% | 6.25% | 5.24% | 9.00% | 7.57% | 7.13% | 8.76% | 9.64% | 11.03% | 11.39% | 12.08% | 12.90% | 12.61% |
| Total Other Income/Expenses | 98.80B | 2.21B | 961.00M | 4.52B | 184.91B | -1.24B | -1.62B | 2.45B | -131.00M | -330.00M | -60.14M | -906.31M | -1.23B | -779.87M | -169.21M | -159.96M | -264.64M |
| Income Before Tax | 879.57B | -107.84B | 1.07B | 7.40B | 979.38B | 9.07B | 6.93B | 15.36B | 9.49B | 7.06B | 8.17B | 6.59B | 5.87B | 5.47B | 5.01B | 4.01B | 3.42B |
| Income Before Tax Ratio | 5.20% | -60.23% | 0.57% | 3.89% | 6.16% | 5.50% | 4.24% | 10.70% | 7.47% | 6.81% | 8.70% | 8.47% | 9.13% | 9.97% | 11.68% | 12.40% | 11.70% |
| Income Tax Expense | 162.26B | -2.19B | 5.34B | 2.48B | 303.09B | 997.00M | 2.14B | 4.33B | 2.90B | 2.47B | 3.04B | 2.68B | 2.01B | 1.70B | 1.56B | 1.34B | 1.02B |
| Net Income | 651.42B | -105.65B | -4.27B | 5.13B | 610.32B | 8.07B | 4.79B | 11.03B | 6.59B | 4.59B | 5.13B | 3.91B | 3.87B | 3.76B | 3.44B | 2.62B | 2.41B |
| Net Income Ratio | 3.85% | -59.00% | -2.27% | 2.70% | 3.84% | 4.90% | 2.93% | 7.69% | 5.19% | 4.43% | 5.46% | 5.03% | 6.01% | 6.86% | 8.03% | 8.10% | 8.23% |
| EPS | 128.01 | -1.50K | -66.65 | 80.28 | 115.33 | 142.92 | 84.08 | 184.44 | 110.25 | 104.73 | 128.14 | 101.54 | 122.50 | 121.98 | 111.83 | 85.75 | 85.70 |
| EPS Diluted | 128.01 | -1.50K | -66.65 | 80.28 | 115.33 | 142.92 | 83.95 | 184.02 | 110.14 | 104.67 | 128.08 | 101.53 | 122.42 | 121.87 | 111.57 | 85.21 | 84.50 |
| Weighted Avg Shares Out | 5.09B | 5.09B | 5.09B | 5.09B | 5.29B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B |
| Weighted Avg Shares Out (Dil) | 5.09B | 5.09B | 5.09B | 5.09B | 5.29B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B | 5.09B |
Source: https://incomestatements.info
Category: Stock Reports